Edgewise Therapeutics, Inc. (EWTX) Earnings Call Transcripts

Edgewise Therapeutics, Inc.'s Latest Earnings Call - June 16, 2026

In the second quarter of 2026, Edgewise Therapeutics, Inc. (EWTX:US) reported significant advancements in its clinical pipeline, particularly with EDG-7500 for hypertrophic cardiomyopathy (HCM). The company announced a definitive agreement with Servier for a total of $1.1 billion in milestone payments and a cash infusion of $1.55 billion, which is expected to enhance its focus on cardiovascular therapies. Revenue and earnings details were not disclosed, but management indicated a strong financial position with $500 million on the balance sheet and no debt. The Phase II trial results for EDG-7500 showed promising efficacy and safety, with management signaling a Phase III initiation planned for Q4 2026.

Reported metrics

Guidance from management

Management expects to initiate Phase III trials for EDG-7500 in Q4 2026 and will provide long-term extension data in the first half of 2027. They indicated that the trial design will not require echo-based titration, which is a significant shift from current practices.

What management said

I think, Anjali, how would you -- looking at this profile, how would you think about how competitive this molecule would be if these were the same results after Phase III, I guess?

Yes. And I think just to add to that, with the open-label extension, we'll be looking at patients beyond this 12-week study and that data will be important in making a decision of the duration of the trial and are there significant differences between the 2 populations.

What analysts pressed on

Analysts expressed concerns regarding the long-term efficacy of EDG-7500 in nonobstructive HCM patients, particularly in relation to KCCQ improvements. There were also questions about the potential for dose titration strategies in the upcoming Phase III trial and how they may impact patient outcomes.

Main topics on the call

• Strategic Partnership with Servier — Edgewise has entered into a definitive agreement with Servier, which includes milestone payments of up to $1.1 billion and a cash infusion of $1.55 billion. CEO Kevin Koch stated, 'We think Servier is an excellent partne...
• EDG-7500 Phase II Trial Results — The Phase II CIRRUS-HCM trial demonstrated a significant reduction in left ventricular outflow tract gradients, with resting gradients dropping from 40 to 18 mmHg, representing over a 50% reduction. Dr. Anjali Owens note...
• Safety Profile of EDG-7500 — No participants experienced a decline in left ventricular ejection fraction (LVEF) below 50%, with Dr. Owens stating, 'We have not observed any detrimental effect on systolic function with 7500 to date.' This supports th...
• Future Phase III Trial Design — Management indicated that the Phase III trial will not require echo-based titration, a significant differentiator from current treatments. Kevin Koch mentioned, 'The agency directly in minutes told us that design looked ...

Read the full Edgewise Therapeutics, Inc. transcript (June 16, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 13 Edgewise Therapeutics, Inc. earnings call transcripts on record, spanning June 9, 2021 to June 16, 2026. Based on this history, Edgewise Therapeutics, Inc. reports semi-annually. The most recent call on file is dated June 16, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

EWTX

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

13

First call

June 9, 2021

Most recent

June 16, 2026

Reporting cadence

semi-annually